Caris Life Sciences Presents Circulating Microvesicle Research Findings at American Urological Association Annual Meeting

Data Shows Diagnostic Promise for Blood-Based Prostate Cancer Detection Test
IRVING, TX, May 18, 2011 — Caris Life Sciences, Inc., a leading bioscience company focused on enabling precise and personalized healthcare through the highest quality anatomic pathology, molecular profiling and blood-based diagnostic services, this weekend presented a poster highlighting the potential of a circulating microvesicle (“cMV”) -based prostate cancer test. The poster, which was presented at the American Urological Association (“AUA”) 2011 Annual Meeting, demonstrated the use of a cMV assay as a potentially powerful diagnostic tool for detecting prostate cancer. Data demonstrated that the assay holds promise as a more accurate aid in the detection of prostate cancer than current testing methods.
“A limitation of traditional tests for prostate cancer screening is that numerous non-malignant processes can also result in PSA elevations,” said Dr. Adam Kibel, the poster’s lead presenter and Director of Urologic Oncology at Washington University in St. Louis. “An assay which detects biomarkers specific for cancer has the potential to improve our ability to detect the presence of cancer. Caris’ development of an assay that enables the isolation, capture, and characterization of cMVs specific to prostate cancer has potential to deliver more accurate diagnoses for these men.”
“We believe that cMVs, which are shed into the bloodstream from both healthy and diseased cells have the potential to improve our diagnostic and prognostic ability in cancer and other complex diseases,” added Dr. Les Paul, Senior Vice President for Research and Development and Chief Technology Officer. “The data we presented at the AUA Annual Meeting represents evidence of the promise of this innovative technology. We look forward to continued scientific development of this important new diagnostic approach to bring more clarity to patients and physicians in overall risk assessment for prostate cancer.”
Caris Life Sciences’ Carisome Technology has the potential to transform healthcare with a blood-based approach to diagnostics, prognostics and therapeutic guidance for clinicians and their patients. Caris’ work in this area is advancing the understanding of cMV and their potential application to patient care.
About Caris Life Sciences
Caris Life Sciences, a leading biosciences company, specializes in the development and commercialization of the highest quality anatomic pathology, molecular profiling, and blood-based diagnostic technologies, in the fields of oncology, dermatopathology, hematopathology, gastrointestinal pathology and urologic pathology. The company provides academic-caliber consultations for thousands of patients a day, through its industry-leading team of expert, subspecialty pathologists. Caris also offers advanced molecular analyses of patient samples through prognostic testing services and genomic, transcriptomic, and proteomic profiling to assist physicians in their treatment of cancer. Currently, Caris is developing a series of blood tests utilizing the patented Carisome™ platform – a proprietary, blood-based testing technology for diagnosis, prognosis, and theranosis of cancer and other complex diseases. The company is headquartered in the Dallas metroplex, and operates laboratories at the headquarters, as well as in the Phoenix and Boston metro areas.
CONTACT: Caris Life Sciences
Media Inquiries:
Holly Clark
Contact Holly